EPILEPSY CLINICAL RESEARCH PROGRAM

癫痫临床研究计划

• 批准号: 6393312
• 负责人: ILO E LEPPIK
• 金额: $ 87.91万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-07-01 至 2002-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6393312
• 关键词: aging; epilepsy; nervous system disorder epidemiology

This program project has been involved in many areas of clinical research over the years, with activities in epidemiology, surgery, genetics and pharmacology of epilepsy. The epidemiological studies have shown that the elderly have the highest incidence and prevalence of epilepsy of any age group, even higher than in the pediatric segment. Furthermore, the elderly are the most rapidly growing segment of the population. Very little is known regarding the effect of aging, co-educations, and co-morbidity on the pharmacology of the antiepileptic drugs (AEDs). This 5 year proposal will use the information and expertise developed in previous years to study metabolism of antiepileptic medications in vitro, in vivo in a large, nursing home population of elderly, to evaluate outcomes of AED use and study race and gender effects on the development of epilepsy. Our epidemiological expertise will be used to evaluate the co- morbidity of epilepsy and vascular disease using the ARIC data base. A major strength of this proposal is the access to large groups of elderly, with over 60,000 elderly in nursing homes through PCA and Beverly Enterprises and 16,000 in the ARIC data base. The elderly especially in these nursing homes are vulnerable to improper AED use and drug toxicity until evidence based guidelines can be developed.

该项目已涉及临床的多个领域 多年来的研究，在流行病学，外科， 癫痫的遗传学和药理学。流行病学研究 已经表明，老年人的发病率和患病率最高 癫痫的发病率在任何年龄段，甚至高于儿科 细分市场。此外，老年人是增长最快的 人口的一部分。我们对此知之甚少。 老龄化、男女共育和共同发病对老年人药理学的影响 抗癫痫药物(AED)。这份为期5年的计划将使用 前几年开发的信息和专门知识以供研究 抗癫痫药物的体外代谢，在体内大量存在， 养老院老年人群使用AED的效果评价 并研究种族和性别对癫痫发病的影响。 我们的流行病学专业知识将被用于评估联合- 使用ARIC数据库研究癫痫和血管疾病的发病率。 这项提议的一个主要优点是可以接触到大量的 老年人，有60,000多名老年人通过PCA和 贝弗利企业和ARIC数据库中的16,000个。老年人 特别是在这些疗养院，很容易受到AED不当使用的影响 和药物毒性，直到基于证据的指南能够被开发出来。